Primidone BE study for USFDA submission [Regulatives / Guidelines]

posted by bebac_fan – US, 2018-04-10 01:11 (1336 d 00:02 ago) – Posting: # 18659
Views: 3,076

Couldn't find any approval packages on [email protected], so I'm going to have to use science rather than precedent, shucks.

PEMA and PHB are both active metabolites, but based on the FDA general guidance, I am not sure that triggers a requirement to test for them.

However, the guidance specifically recommends PK samples for metabolites when there may be gut/enteric metabolism. Primidone undergoes autoinduction so it is likely metabolized by 3A4, which is in the gut. I suppose this is a trigger for metabolite monitoring?

Another point about autoinduction, is there are persistent effects on metabolism. A long washout period, determined by turnover number of CYPs should be applied. I am not sure what you guys do in practice. PHB can hang with the best of them (like rifampin) in terms of induction.

Complete thread:

Activity
 Admin contact
21,785 posts in 4,556 threads, 1,547 registered users;
online 4 (0 registered, 4 guests [including 2 identified bots]).
Forum time: Monday 00:13 CET (Europe/Vienna)

The history of statistics is like a telephone directory:
the plot is boring, full of numbers and the cast is endless.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5